DOCSLIB.ORG

Author's Personal Copy

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Author's Personal Copy Author's personal copy Biomaterials 31 (2010) 2358–2370 Contents lists available at ScienceDirect Biomaterials journal homepage: www.elsevier.com/locate/biomaterials Self-assembling methoxypoly(ethylene glycol)-b-poly(carbonate-co-L-lactide) block copolymers for drug delivery Michael Danquah a, Tomoko Fujiwara b, Ram I. Mahato a,* a Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, 19 South Manassas (Room 224), Memphis, TN 38103-3308, USA b Department of Chemistry, The University of Memphis, Memphis, TN 38152, USA article info abstract Article history: Bicalutamide is the most widely used non-steroidal antiandrogen for treating early stage prostate Received 11 September 2009 cancer, but suffers variable oral absorption due to its limited aqueous solubility. Thus, our objective was Accepted 24 November 2009 to synthesize novel biodegradable copolymers for the systemic micellar delivery of bicalutamide. Available online 17 December 2009 Flory–Huggins interaction parameter (cFH) was used to assess compatibility between bicalutamide and poly(L-lactide) or poly(carbonate-co-lactide) polymer pairs. Polyethylene glycol-b-poly(carbonate-co- Keywords: lactide) [PEG-b-P(CB-co-LA)] copolymers were synthesized and characterized by NMR and gel Micelles permeation chromatography. These micelles had average diameter of 100 nm and had a smooth surface Copolymer Polyethylene glycol and distinct spherical shape. Drug loading studies revealed that adding the carbonate monomer could Polycarbonate increase bicalutamide loading. Among the series, drug loading of micelles formulated with PEG-b-P(CB- Poly lactic acid co-LA) copolymer containing 20 mol% carbonate was about four-fold higher than PEG-b-PLLA and Bicalutamide aqueous solubility of bicalutamide increased from 5 to 4000 mg/mL. CMC values for PEG-b-P(CB-co-LA) copolymers was up to 10-fold lower than those of PEG-b-PLLA. In vitro release experiments showed PEG-b-P(CB-co-LA) copolymers to be more efficient in sustaining the release of bicalutamide compared to PEG-b-PLLA. Bicalutamide-loaded PEG-b-P(CB-co-LA) micelles showed significant inhibition of LNCaP cell growth in a dose-dependent manner which was similar to the methanol solution of free drug. Ó 2009 Elsevier Ltd. All rights reserved. 1. Introduction One way of improving the solubility of hydrophobic drugs and in particular bicalutamide is by using polymeric micelles. Micelles are Androgens are known to play a pivotal role in the development attractive drug delivery vehicles primarily because they can solu- and maintenance of the prostate by interacting with the androgen bilize hydrophobic drugs in their core leading to improved receptor (AR) [1]. Consequently, androgen ablation, especially the bioavailability and drug stability. Furthermore, micelles are capable use of antiandrogens, has been used as a standard treatment for of preventing drug degradation, minimizing the adverse effects of men with prostate cancer. Among various antiandrogens, bicaluta- the drug on visceral organs and have the possibility of being made mide (CasodexÔ) is the most widely used non-steroidal anti- site-specific [4]. A number of amphiphilic diblock copolymers androgen for treating early stage prostate cancer due to its relatively composed of polyethylene glycol (PEG) and various biodegradable long half life and tolerable side effects [2]. However, bicalutamide hydrophobic cores capable of forming micelles have been reported exhibits poor aqueous solubility (5 mg/mL), which results in poor in the literature. Examples include: poly(ethylene glycol)-b-poly- and variable drug absorption across the gastro intestinal tract. (aspartic acid) [PEG-b-PAA] [5], poly(ethylene glycol)-b-poly(lac- Furthermore, bicalutamide cannot be administered systemically, as tide-co-glycolic acid) [PEG-b-PLGA][6], poly(ethylene glycol)-b- traditional approaches to increase its aqueous solubility using poly(caprolactone) [PEG-b-PCL] [7] and poly(ethylene glycol)-b- solubilizing agents such as dimethyl sulfoxide (DMSO) and Cre- poly(D,L-lactide) [PEG-b-PDLLA] [8]. Key properties of these micelle mophor EL is not practical in humans due to hemolysis, acute systems such as size, stability, drug release kinetics and drug loading hypertensive reactions and neuropathies [3]. have also been well studied. We have recently demonstrated the feasibility of using PEG-b- PDLLA micelles to increase the aqueous solubility of bicalutamide * Corresponding author. Tel.: þ1 901 448 6929; fax: þ1 901 448 2099. E-mail address: [email protected] (R.I. Mahato). [9]. Although we were able to increase the aqueous solubility of URL: http://www.uthsc.edu/pharmacy/rmahato bicalutamide, we observed only moderate drug loading levels 0142-9612/$ – see front matter Ó 2009 Elsevier Ltd. All rights reserved. doi:10.1016/j.biomaterials.2009.11.081 Author's personal copy M. Danquah et al. / Biomaterials 31 (2010) 2358–2370 2359 which may not be high enough for systemic administration. To 2.2. Computation of solubility and Flory–Huggins interaction parameters (cFH)of solve this problem, the focus of the present study was to specifically bicalutamide with core of PEG-b-PLLA/PEG-poly(carbonate-co-lactide) micelles design and develop a new family of biodegradable amphiphilic The Flory–Huggins interaction parameter (cFH) which characterizes polymer– copolymers to improve the aqueous solubility of bicalutamide by drug compatibility was calculated using equations (1) and (2): enhancing its loading levels. Our strategy involves modifying the hÀ Á À Á À Á i1 polyester component of the well established PEG-b-polyester 2 2 2 2 D ¼ dd À dp polarityþ dd þ dp dispersionþ dd À dp hydrogen (1) copolymer into polyester/polycarbonate copolymer system. The semicrystalline poly(L-lactide) was chosen as the polyester block D2V c ¼ d (2) because it is FDA approved, possesses good mechanical properties FH RT which may provide adequate stability to the micelle system and is where D2 is the solubility difference between the drug (d) and the core of the known for its application as a drug delivery material [10–12]. For polymeric micelle (p). Vd is the molar volume of the drug, T is the temperature in the carbonate block we selected the cyclic 5-methyl-5-benzylox- Kelvin and R is the gas constant. The Hansen partial solubility parameters [(d ) ,(d ) ,(d ) ] for the drug (bica- ycarbonyl-1,3-dioxane-2-one carbonate monomer. 5-methyl-5- x d x p x h lutamide) and the hydrophobic block of PEG-b-PLLA and PEG-b-poly(carbonate-co- benzyloxycarbonyl-1,3-dioxane-2-one is a modification of 5-ben- lactide) [PEG-b-P(CB-co-LA)] copolymers used in equation (1) were estimated using zyloxycarbonyl-1,3-dioxane-2-one which is an intermediate in the the Molecular Modeling Pro software from ChemSW (Fairfield, CA). This software synthesis of numerous antiviral compounds [13]. This carbonate approximates solubility parameters using the Hansen theory of solubility group monomer was chosen since polycarbonates are biodegradable, contribution method. (dx)d,(dx)p and (dx)h refers to the partial solubility parameters accounting for Van der Waals forces of dispersion between atoms, permanent exhibit low toxicity and possess tunable mechanical properties dipole–dipole forces between molecules and the proclivity of molecules hydrogen [14–16]. Furthermore, polycarbonate degrades into carbon dioxide bonding, respectively. Here, subscript x refers to the drug or polymer core. and benzyl alcohol, which unlike the degradation products of poly(L-lactide) [e.g. lactic acid] are less acidic, has less effect on 2.3. Synthesis of 5-methyl-5-benzyloxycarbonyl-1,3-dioxane-2-one microenvironment pH and as such will not result in local inflam- A mixture of 2,2-bis(hydroxymethyl)propionic acid (22.5 g, 0.168 mol), potas- mation. We hypothesize that the introduction of the carbonate sium hydroxide (88% assay; 10.75 g, 0.169 mol), and dimethylformamide (DMF) monomer would provide additional degrees of freedom to tailor (125 mL) was heated to 100 C for 1 h with stirring at which point homogenous a micelle delivery system that is relatively stable, exhibits improved potassium salt solution was formed. Benzyl bromide (34.5 g, 0.202 mol) was added sustained release and has a hydrophobic core that is more dropwise to the warm solution, and stirring was continued at 100 C for 15 h. Upon completion of the reaction, the mixture was cooled and the solvent was removed compatible with bicalutamide leading to enhanced drug loading. under vacuum. The residue was dissolved in ethyl acetate (150 mL), hexanes Improvement in the extent of compatibility between a drug and (150 mL), and water (100 mL). The organic layer was retained, washed with water the core-forming block of the micelle may translate into superior (100 mL), dried (Na2SO4), and evaporated. The resulting solid was recrystallized encapsulation efficiency [17–20]. A number of groups have from toluene to give pure benzyl 2,2-bis(methylol)propionate, as white crystals explored the possibility of predicting drug solubilization in micelles (20 g, 58%). Benzyl 2,2-bis(methylol)propionate (11.2 g, 0.05 mol) was dissolved in pyridine based on thermodynamics and found their predictions to closely (25 mL, 0.3 mol) and CH2Cl2 (150 mL), and the solution was chilled to À78 C under approximate experimental results [18,21–23]. Polymer/drug N2. A solution of triphosgene (7.5 g, 25.0 mmol) in CH2Cl2 was added dropwise over compatibility may be characterized by the Flory–Huggins interac- 1 h, after which the reaction mixture was stirred at room temperature for 2 h. The reaction was quenched by the addition of saturated aqueous NH4Cl (75 mL). Subse- tion parameter (cFH) which accounts for the forces of interaction quently, the organic layer was washed with 1 M aqueous HCl (3 Â 100 mL), saturated between the polymer and the drug; and low cFH values suggest that aqueous NaHCO3 (1 Â 100 mL), dried (Na2SO4), filtered and evaporated to give 5- the polymer is thermodynamically a good solvent for the drug.
Load more

Recommended publications
  • Photoaging & Skin Damage
    Use_for_Revised_OFC_Only_2006_PhotoagingSkinDamage 5/21/13 9:11 AM Page 2 PEORIA (309) 674-7546 MORTON (309) 263-7546 GALESBURG (309) 344-5777 PERU (815) 224-7400 NORMAL (309) 268-9980 CLINTON, IA (563) 242-3571 DAVENPORT, IA (563) 344-7546 SoderstromSkinInstitute.comsoderstromskininstitute.com FROMFrom YOUR Your DERMATOLOGISTDermatologist [email protected]@skinnews.com PHOTOAGING & SKIN DAMAGE Before You Worship The Sun Who’s At Risk? Today, many researchers and dermatologists Skin types that burn easily and tan rarely are believe that wrinkling and aging changes of the skin much more susceptible to the ravages of the sun on the are much more related to sun damage than to age! skin than are those that tan easily, rather than burn. Many of the signs of skin damage from the sun are Light complected, blue-eyed, red-haired people such as pictured on these pages. The decrease in the ozone Swedish, Irish, and English, are usually more suscep- layer, increasing the sun’s intensity, and the increasing tible to photo damage, and their skin shows the signs sun exposure among our population – through work, of photo damage earlier in life and in a more pro- sports, sunbathing and tanning parlors – have taken a nounced manner. Dark complexions give more protec- tremendous toll on our skin. Sun damage to the skin tion from light and the sun. ranks with other serious health dangers of smoking, alcohol, and increased cholesterol, and is being seen in younger and younger people. NO TAN IS A SAFE TAN! Table of Contents Sun Damage .............................................Pg. 1 Skin Cancer..........................................Pgs. 2-3 Mohs Micrographic Surgery ......................Pg.
    [Show full text]
  • Glycolic Acid
    Glycolic Acid Pharmacy Compounding Advisory Committee Meeting November 3, 2016 Jane Liedtka, MD Clinical Reviewer Division of Dermatology and Dental Products, Office of Drug Evaluation III Glycolic Acid Review Team Jane Liedtka, MD, Clinical Reviewer, DDDP, ODE3 Ben Zhang, PhD, Chemistry Reviewer, OPQ Jianyong Wang, PhD, Pharmacology/Toxicology Reviewer, DDDP, ODE3 Doanh Tran, PhD., Clinical Pharmacology Team Leader, DCP3, OCP www.fda.gov 2 Nomination • Glycolic acid, 0.08% to 70%, has been nominated for inclusion on the list of bulk drug substances for use in compounding under section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for topical use in the treatment of hyperpigmentation disorders and photodamaged skin www.fda.gov 3 Background • Glycolic acid is currently available in cosmetic formulations (creams, pads, and lotions) and present as excipient in some topical drug products www.fda.gov 4 Regulatory Definitions: Drugs and Cosmetics • Whether a product is a cosmetic or a drug under the law is determined by a product's intended use; different laws and regulations apply to each type of product • A drug is an article intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or an article (other than food) that is intended to affect the structure or function of the body • A cosmetic is an article (other than soap) intended to be rubbed, poured, sprinkled, or sprayed on, introduced into, or otherwise applied to the human body for cleansing, beautifying, promoting attractiveness, or altering appearance – Regulated by CFSAN – No premarket approval of products or ingredients (except color additives) www.fda.gov 5 Cosmetic and Drug Uses of Topical Acids • Topical Acids cause exfoliation, or shedding of the skin surface.
    [Show full text]
  • Acne Treatment: Easy Ways Hospital Family Medicine Residency Program, French Camp, Calif to Improve Your Care [email protected]
    CASE c Tam T. Nguyen, MD San Joaquin General Acne treatment: Easy ways Hospital Family Medicine Residency Program, French Camp, Calif to improve your care [email protected] The author reported no For patients of any age, facial lesions can cause potential conflict of interest relevant to this article. considerable embarrassment and distress. Read on to discover what key component of acne treatment you should be using (but probably aren’t) and which dosage you can safely lower. c Practice CASE Janis S, an otherwise healthy 19-year-old, is in your recommendations office, seeking treatment for acne. She reports she has tried various over-the-counter (oTc) creams in recent months, but › Use a classification system, has seen little improvement. The acne first appeared about such as that of the American 5 years ago, and her pediatrician prescribed topical adapalene Academy of Dermatol- and doxycycline. The treatment helped, but she says her face ogy, to assess the severity never fully cleared up; over the past year, the acne has gotten of acne vulgaris. A worse. › Treat inflamma- on examination, you find several nodules and comedones tory lesions aggressively on the patient’s face, chest, and back. ms. S confides in you to prevent scarring. A that the acne—particularly on her face—kept her from going › When isotretinoin is to the senior prom. indicated, consider prescrib- ing a lower dosage (but ore than 80% of adolescents and adults develop longer duration) than the acne vulgaris at some point in their lives, and in traditional regimen. B at least 15% to 20% of cases, the acne is moderate M1 Strength of recommendation (SOR) to severe.
    [Show full text]
  • PDO Thread Lift and Smoothing
    PDO Thread Li and Smoothing Pre-Care and Post-Care Instrucons Pre-Care Instrucons 2 WEEKS BEFORE: ● Avoid taking (unless medically necessary) aspirin, non-steroidal an-inflammatory medicaons such as ibuprofen, Aleve, Advil, Motrin or supplements such as St. John’s Wort, Vitamin E, Fish oil/Omega 3/Flax Seed oil or Melatonin. These agents may increase bruising and bleeding risk. Tylenol is acceptable. Please let Renew Med Spa know if you are on any medicaon, such as blood thinners, that may increase your risk of bruising and/or bleeding. 1 WEEK BEFORE: ● Avoid any topical skincare products that may irritate your skin such as glycolic acid, salicylic acid or renoic (renols) acids. ● If you have any recent skin injecon, acve acne or cold sore in the treatment area, please call our office immediately to reschedule your appointment. 1 DAY BEFORE: ● Oral Arnica should be taken to minimize risk of swelling and bruising. Take Arnica the day before your treatment. ● Please nofy Renew Med Spa or our staff if you have a history of more than 3 facial cold sores a year, as there is a risk that this procedure could cause a recurrence. You can take Valtrex, 2 grams the night before your procedure and another 2 grams 12 hours aer the procedure to prevent cold sores recurrence. DAY OF PROCEDURE: ● Local numbing medicaon will be used to maximize your comfort during the procedure. Most paents report a mild to moderate snging sensaon with numbing injecons. It is important to discuss any sensivity or allergy to Lidocaine, Novocaine or Epinephrine with your provider prior to treatment.
    [Show full text]
  • Inside This Issue
    Volume 5 | Issue 1 | SkinCare Physicians | 2008 Edition 1244 Boylston Street, Chestnut Hill, MA 02467 | Phone: (617) 731-1600 | Fax: (617) 731-1601 SKINCARE PRESCRIPTION ARRIVES ! After years of exhaustive research and development, on the market, it can be confusing. To simplify SkinCare Physicians is proud to introduce our the skin care process, we have chosen the most new proprietary line of products, SKINCARE innovative and important ingredients available to PRESCRIPTION. With over 100 years of combined create a line of 8 products that our patients can use experience and expertise in skin care, the daily to care for their skin. dermatologists at SkinCare Physicians are uniquely positioned to develop this innovative product line. Unlike all the other products out there, SKINCARE The 8 products include: PRESCRIPTION is different. • Cleanser • Exfoliator The concept behind SKINCARE PRESCRIPTION is • Day Anti-Aging Moisturizer AHA with SPF 15 simple: provide a small group of carefully chosen • Night Anti-Aging Moisturizer with Retinol products that actually improve your skin, and at a • Anti-Aging Eye Cream reasonable price. Most patients use many different • Intensive Anti-Wrinkle Moisturizer (with the products, are never sure just which ones to use SkinCare Physicians special formula) when, and pay too much for them. Every day patients • Age Prevention Vitamin C Serum ask us about the products they should use to keep • Age Reversal Glycolic Acid Serum 10% their skin healthy and young looking, and because there are so many different products to choose from ( continued on page 2 ) YOUTH IN A SYRINGE: THE NEW WAY TO GET DRAMATIC RESULTS WITH FILLERS AND BOTOX INSIDE THIS ISSUE: While it may sound too good to be true, it has never lines between the eyes by combining Restylane been easier to achieve extraordinary results that can or Juvederm with Botox, creating improvement make you look younger in minutes.
    [Show full text]
  • Title Dimethyl Carbonate As Potential Reactant in Non-Catalytic
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Kyoto University Research Information Repository Dimethyl carbonate as potential reactant in non-catalytic Title biodiesel production by supercritical method Author(s) Ilham, Zul; Saka, Shiro Citation Bioresource Technology (2009), 100(5): 1793-1796 Issue Date 2009-03 URL http://hdl.handle.net/2433/87775 Right c 2009 Elsevier Ltd All rights reserved. Type Journal Article Textversion author Kyoto University Dimethyl Carbonate as Potential Reactant in Non-Catalytic Biodiesel Production by Supercritical Method Zul Ilham and Shiro Saka* Department of Socio-Environmental Energy Science, Graduate School of Energy Science, Kyoto University, Yoshida-honmachi, Sakyo-ku, Kyoto 606-8501, Japan *Corresponding author: Shiro Saka Department of Socio-Environmental Energy Science, Graduate School of Energy Science, Kyoto University, Yoshida-honmachi, Sakyo-ku, Kyoto 606-8501, Japan Tel : +81-75-753-4738 Fax: +81-75-753-4738 E-mail address: [email protected] 1 Abstract In this study, the non-catalytic supercritical method has been studied in utilizing dimethyl carbonate. It was demonstrated that, the supercritical dimethyl carbonate process without any catalysts applied, converted triglycerides to fatty acid methyl esters with glycerol carbonate and citramalic acid as by-products, while free fatty acids were converted to fatty acid methyl esters with glyoxal. After 12 min of reaction at 350 °C/20 MPa, rapeseed oil treated with supercritical dimethyl carbonate reached 94% (w/w) yield of fatty acid methyl ester. The by-products from this process which are glycerol carbonate and citramalic acid are much higher in value than glycerol produced by the conventional process.
    [Show full text]
  • APPENDIX G Acid Dissociation Constants
    harxxxxx_App-G.qxd 3/8/10 1:34 PM Page AP11 APPENDIX G Acid Dissociation Constants §␮ ϭ 0.1 M 0 ؍ (Ionic strength (␮ † ‡ † Name Structure* pKa Ka pKa ϫ Ϫ5 Acetic acid CH3CO2H 4.756 1.75 10 4.56 (ethanoic acid) N ϩ H3 ϫ Ϫ3 Alanine CHCH3 2.344 (CO2H) 4.53 10 2.33 ϫ Ϫ10 9.868 (NH3) 1.36 10 9.71 CO2H ϩ Ϫ5 Aminobenzene NH3 4.601 2.51 ϫ 10 4.64 (aniline) ϪO SNϩ Ϫ4 4-Aminobenzenesulfonic acid 3 H3 3.232 5.86 ϫ 10 3.01 (sulfanilic acid) ϩ NH3 ϫ Ϫ3 2-Aminobenzoic acid 2.08 (CO2H) 8.3 10 2.01 ϫ Ϫ5 (anthranilic acid) 4.96 (NH3) 1.10 10 4.78 CO2H ϩ 2-Aminoethanethiol HSCH2CH2NH3 —— 8.21 (SH) (2-mercaptoethylamine) —— 10.73 (NH3) ϩ ϫ Ϫ10 2-Aminoethanol HOCH2CH2NH3 9.498 3.18 10 9.52 (ethanolamine) O H ϫ Ϫ5 4.70 (NH3) (20°) 2.0 10 4.74 2-Aminophenol Ϫ 9.97 (OH) (20°) 1.05 ϫ 10 10 9.87 ϩ NH3 ϩ ϫ Ϫ10 Ammonia NH4 9.245 5.69 10 9.26 N ϩ H3 N ϩ H2 ϫ Ϫ2 1.823 (CO2H) 1.50 10 2.03 CHCH CH CH NHC ϫ Ϫ9 Arginine 2 2 2 8.991 (NH3) 1.02 10 9.00 NH —— (NH2) —— (12.1) CO2H 2 O Ϫ 2.24 5.8 ϫ 10 3 2.15 Ϫ Arsenic acid HO As OH 6.96 1.10 ϫ 10 7 6.65 Ϫ (hydrogen arsenate) (11.50) 3.2 ϫ 10 12 (11.18) OH ϫ Ϫ10 Arsenious acid As(OH)3 9.29 5.1 10 9.14 (hydrogen arsenite) N ϩ O H3 Asparagine CHCH2CNH2 —— —— 2.16 (CO2H) —— —— 8.73 (NH3) CO2H *Each acid is written in its protonated form.
    [Show full text]
  • WO 2018/227293 Al 20 December 2018 (20.12.2018) W ! P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/227293 Al 20 December 2018 (20.12.2018) W ! P O PCT (51) International Patent Classification: c/o Jack Bell Research Centre, 2660 Oak Street, Vancouver, A61K 47/30 (2006.01) C08G 63/08 (2006.01) British Columbia V6H 3Z6 (CA). A61K 47/10 (2017.01) C08G 65/28 (2006.01) (74) Agent: MACINS, Andris; Unit 203A - 116 Geary Avenue, A61K 47/34 (2017.01) Toronto, Ontario M6H 4H1 (CA). (21) International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/CA20 18/0507 14 kind of national protection available): AE, AG, AL, AM, (22) International Filing Date: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 13 June 2018 (13.06.2018) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (25) Filing Language: English HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, (26) Publication Language: English KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (30) Priority Data: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 62/5 18,800 13 June 2017 (13.06.2017) US SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (71) Applicant: THE UNIVERSITY OF BRITISH COLUM¬ TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • Ep 2937372 A1
    (19) TZZ ¥¥ _T (11) EP 2 937 372 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 28.10.2015 Bulletin 2015/44 C08G 64/30 (2006.01) (21) Application number: 14382152.8 (22) Date of filing: 25.04.2014 (84) Designated Contracting States: • Bojarski, Aaron David AL AT BE BG CH CY CZ DE DK EE ES FI FR GB 30390 La Aljorra, Cartagena (AR) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO • Vic Fernández, Ignacio PL PT RO RS SE SI SK SM TR 30390 La Aljorra, Cartagena (ES) Designated Extension States: BA ME (74) Representative: Modiano, Micaela Nadia Modiano & Partners (DE) (71) Applicant: SABIC Global Technologies B.V. Thierschstrasse 11 4612 PX Bergen op Zoom (NL) 80538 München (DE) (72) Inventors: • Garcia Agudo, Jorge A 30390 La Aljorra, Cartagena (ES) (54) AMETHOD OF MELT POLYMERIZING POLYCARBONATE AND POLYCARBONATES DERIVED THEREFROM (57) In an embodiment, a melt polymerization proc- sition comprises an alpha catalyst and a beta catalyst ess can comprise: melt polymerizing a dihydroxy com- comprising TPPP, wherein the polymerized polycar- pound and a carbonate compound in a polymerization bonate has a branching level of less than or equal to 900 unit in the presence of a catalyst composition to form ppm. polymerized polycarbonate, wherein the catalyst compo- EP 2 937 372 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 937 372 A1 Description TECHNICAL FIELD 5 [0001] This application relates to catalysts in a melt polymerization and to processes of using the same, and especially relates to a melt polymerization process using a catalyst comprising tetraphenyl phosphonium phenolate.
    [Show full text]
  • Process for Simultaneous Production of Ethylene Glycol and Carbonate Ester
    Europäisches Patentamt *EP001125915B1* (19) European Patent Office Office européen des brevets (11) EP 1 125 915 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.7: C07C 68/06, C07C 29/128, of the grant of the patent: C07C 31/20 25.05.2005 Bulletin 2005/21 (21) Application number: 01100972.7 (22) Date of filing: 17.01.2001 (54) Process for simultaneous production of ethylene glycol and carbonate ester Verfahren zur gleichzeitigen Herstellung von Ethylenglykol und Carbonatester Procédé pour la production simultanée d’éthylèneglycol et d’ester carbonate (84) Designated Contracting States: (74) Representative: DE ter Meer, Nicolaus, Dipl.-Chem., Dr. TER MEER STEINMEISTER & PARTNER GbR, (30) Priority: 19.01.2000 JP 2000009865 Patentanwälte, Mauerkircherstrasse 45 (43) Date of publication of application: 81679 München (DE) 22.08.2001 Bulletin 2001/34 (56) References cited: (73) Proprietor: Mitsubishi Chemical Corporation WO-A-99/64382 US-A- 5 214 182 Tokyo 108-0014 (JP) US-A- 5 847 189 (72) Inventor: Kawabe, Kazuki, Mitsubishi Chemical Corporation Yokkaichi-shi, Mie (JP) Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention). EP 1 125 915 B1 Printed by Jouve, 75001 PARIS (FR) EP 1 125 915 B1 Description [0001] The present invention relates to an efficient process for simultaneously producing ethylene glycol and a car- bonate ester as industrial materials, especially ethylene glycol important as a raw material for polyester resin and a 5 carbonate ester such as dimethyl carbonate useful as a raw material for polycarbonate resin.
    [Show full text]
  • Felix Ekness
    ABSTRACT A Synthetic Biology Approach to Engineering Bacterial Two- Component Systems for Sensor Development and Discovery of Anti-Virulence Agents by Felix Ekness Bacterial two-component systems (TCSs) are the largest family of signal transduction pathways that enable bacteria to sense a diversity of stimuli including small peptides, environmental pollutants, and light. Canonical TCSs are composed of a transmembrane sensor histidine kinase (SK) that converts stimulus detection into phosphorylation of a cognate response regulator (RR). Upon phosphorylation, the cytoplasmic RR binds target output promoters, hereby modulating gene expression. TCSs are valuable sensors for synthetic biology due to their diverse sensing capabilities and straightforward transduction of detected stimulus into transcriptional regulation. TCSs are also emerging targets for novel therapeutic development due to their extensive role in regulating bacterial virulence and antibiotic resistance. Although TCSs are exciting sensors for synthetic biology and targets for therapeutic applications, most TCSs remain difficult to harness for applications and study due to output promoters that are unknown, subject to cross- regulation, or silent in heterologous hosts. In the first portion of my work, I develop a method to overcome the hurdles in characterizing and utilizing TCSs as biosensors. Through the framework of synthetic biology, I demonstrate that the two largest families of RR DNA binding domains (DBDs) can be interchanged with remarkable flexibility, enabling the corresponding TCSs to be rewired to synthetic output promoters. In collaboration with Kristina Daeffler, we exploit this plasticity to eliminate cross-regulation and in collaboration with Brian Landry, we un-silence a gram-negative TCS in a gram-positive host and engineer a sensor with over 1,300-fold activation.
    [Show full text]
  • Functional Cyclic Carbonate Monomers and Polycarbonates
    “[…] patience is sometimes the best policy” — Leonard, J.; Lygo, B.; Procter, G. Advanced Practical Organic Chemistry. Till Krypet List of Papers This thesis is based on the following papers, which are referred to in the text by their Roman numerals. I Efficient DNA Binding and Condensation Using Low Mole- cular Weight, Low Charge Density Cationic Polymer Am- phiphiles Mindemark, J.; Bowden, T. Macromolecular Rapid Communications 2010, 31, 1378–1382 II Low Charge Density Cationic Polymers for Gene Delivery: Exploring the Influence of Structural Elements on In Vitro Transfection Mindemark, J.; Tabata, Y.; Bowden, T. Accepted for publication in Macromolecular Bioscience III Synthesis and polymerization of alkyl halide-functional cyc- lic carbonates Mindemark, J.; Bowden, T. Polymer 2011, 52, 5716–5722 IV Diversity in cyclic carbonates: Synthesis of triazole- functional monomers using click chemistry Mindemark, J.; Bowden, T. Submitted manuscript Reprints were made with permission from the respective publishers. Contents 1 Introduction ......................................................................................... 11 1.1 Polymers ......................................................................................... 11 1.2 Polymers as biomaterials ................................................................ 12 1.2.1 Biodegradable polyesters and polycarbonates ....................... 13 1.2.2 Functional polymers .............................................................. 15 1.3 Cyclic carbonate monomers ...........................................................
    [Show full text]